ArticleAnnals of surgical oncology2021
Time to Completion of Breast Cancer Treatment and Survival.
Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ethnoracial disparities in breast cancer treatment time and survival: a systematic review with a DAG-based causal model.Epidemiologic reviews · 2025Pooled it
- Effect of the SARS-CoV-2 pandemic on the opportunity to treat patients with breast cancer: experience at a reference cancer center in Mexico City.Cancer causes & control : CCC · 2026Observational
- Association between time to treatment and financial toxicity among women with breast cancer in Ethiopia: a multicentre study in a low-resource setting.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- The rural-urban paradox: rethinking delays in breast cancer care.Gland surgery · 2026Article
- Impact of Quality Improvement Interventions on Biopsy-to-Treatment Time in Breast Cancer: Results from the PROMPT Quality Collaborative of the National Accreditation Program for Breast Centers.Annals of surgical oncology · 2025Article
- Time From Screening to Treatment at Accredited Breast Centers in the United States.JCO oncology practice · 2025Article
- Article
- pH-responsive nano-vaccine combined with anti-PD-1 antibodies for enhanced immunotherapy of breast cancer.Theranostics · 2025Article
- A latent class assessment of healthcare access factors and disparities in breast cancer care timeliness.PLoS medicine · 2024Article
- Patient-reported observations on medical procedure timeliness (PROMPT) in breast cancer: a qualitative study.Breast cancer research and treatment · 2024Article
- Residual cancer burden in two-stage nipple sparing mastectomy after first stage lumpectomy and devascularization of the nipple areolar complex.Breast cancer research and treatment · 2024Article
- Favorable outcome of neoadjuvant endocrine treatment than surgery-first in female HR-positive/HER2-negative breast cancer patients-A NCDB analysis (2010-2016).Cancer medicine · 2024Article
- Race, geography, and risk of breast cancer treatment delays: A population-based study 2004-2015.Cancer · 2023Article
- Development of a key performance indicator for breast cancer in Queensland, Australia.Breast cancer research and treatment · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer treatment delays are common. This study was designed to examine the association between the time interval from time of diagnosis to completion of all acute breast cancer treatment modalities (surgery, chemotherapy, and radiation therapy) and survival.
methodsA retrospective analysis was performed utilizing data from the National Cancer Database (NCDB) to determine an association between the duration of time from diagnosis to completing all acute breast cancer treatment (surgery, chemotherapy, and radiation therapy) and survival. Secondary survival analysis evaluated whether delay in treatment completion varied by differences in tumor receptor status.
resultsWe analyzed 2010 NCDB data of stage I-III breast cancer patients. A subset of 28,284 patients received all three modalities (surgery, chemotherapy, and radiation) as their acute treatment. Median follow-up was 5.8 years. Cox proportional hazards model identified a cut-off showing the risk of delaying completion of all treatment beyond 38 weeks was associated with a decrease in overall survival (hazard ratio [HR] 1.21). This decrease in survival was significant regardless of the major tumor receptor status: triple-negative (HR 1.188, 95% confidence interval [CI] 1.06-1.34), estrogen receptor (ER)+/progesterone receptor (PR)+/human epidermal growth factor receptor 2 (HER2)- (HR 1.22, 95% CI 1.09-1.36), ER-/PR-/HER2+ (HR 1.29, 95% CI 1.004-1.67), and ER+/PR+/HER2+ (HR 1.32, 95% CI 1.01-1.72).
conclusionEfforts to improve the efficiency of multimodality breast cancer treatment and reduce treatment delays should be a priority to optimize breast cancer patient outcomes.
Indexed as
Identifiers
34105030What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.